| Literature DB >> 22702513 |
Bhaskar Reddy Kusuma1, Liang Zhang, Teather Sundstrom, Laura B Peterson, Rick T Dobrowsky, Brian S J Blagg.
Abstract
Compound 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death of primary sensory neurons and reverses numerous clinical indices of diabetic peripheral neuropathy in mice. The current study sought to exploit the C-terminal binding site of Hsp90 to determine whether the optimization of hydrogen bonding and hydrophobic interactions of second-generation novologues could enhance neuroprotective activity. Using a series of substituted phenylboronic acids to replace the coumarin lactone of 2, we identified that electronegative atoms placed at the meta-position of the B-ring exhibit improved cytoprotective activity, which is believed to result from favorable interactions with Lys539 in the Hsp90 C-terminal binding pocket. Consistent with these results, a meta-3-fluorophenyl substituted novologue (13b) exhibited a 14-fold lower ED(50) for protection against glucose-induced toxicity of primary sensory neurons compared to 2.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22702513 PMCID: PMC3390240 DOI: 10.1021/jm300544c
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446